BioPharmSignal logoBioPharmSignal

Biotech News

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Rigel Pharmaceuticals (RIGL)Rigel PharmaceuticalsClinical readout

RIGL (RIGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rigl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KPTIKaryopharm Therapeutics2026-06-02 12:59 EST

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-04-21 14:00 EST

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

APTOAptose Biosciences, Inc.2025-11-03 14:00 EST

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

APVOAptevo Therapeutics2026-05-06 12:05 EST

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APTOAptose Biosciences, Inc.2026-06-15 11:30 EST

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

ZNTLZentalis2026-05-21 21:39 EST

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

ZNTLZentalis2026-05-05 12:00 EST

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

View all latest news

Rigel Pharmaceuticals

Hematology and Oncology Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer. It combines a growing portfolio of marketed medicines with internally developed and licensed clinical programs. TAVALISSE TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune...

Recent company news

RIGLRigel Pharmaceuticals2026-08-04 20:01 EST

Rigel Reports Second Quarter 2026 Financial Results

RIGLRigel Pharmaceuticals2026-07-28 12:05 EST

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

RIGLRigel Pharmaceuticals2026-07-01 12:05 EST

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

RIGLRigel Pharmaceuticals2026-06-16 20:01 EST

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

RIGLRigel Pharmaceuticals2026-05-27 12:05 EST

Rigel to Present at the Jefferies Global Healthcare Conference

Stock data

Close
39.22 USD
Market cap
555.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States